EMA: about to reveal all?
This article was originally published in Scrip
Executive Summary
On 2 October, the European Medicines Agency's management board will finally adopt its policy on proactive release of clinical trial data, marking the concluding stage of a remarkable journey through the complexities of commercial confidentiality and patient privacy in search of some sort of equilibrium between the interests of the pharmaceutical industry and those of public health.